blood clot thrombosis
Conditions
Interventions
Sponsors
Gelre Ziekenhuizen
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Cancer (of any type, any stage) diagnosis - Prior history of VTE (regarding population of 100 patients) or no history of VTE (population of 278 patients)
Exclusion criteria
Exclusion criteria: - Previously documented coagulation defects - Prior history of venous thromboembolism (regarding the population of 278 patients) - Age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main clinical outcome of the current study is the occurrence of a thrombotic event in the cancer patient cohort. Blood will be collected at baseline patient inclusion and several coagulation tests described below will be performed. The results of these tests will be compared between the group of patients that did and did not suffer from thrombosis, with the aim of discovering potential biomarkers that allow for prediction of thrombosis risk in a cancer patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Objectives The secondary objective of this study is to determine the effect of the cancer type and stage and the effect of treatment on the probability to develop thrombosis. Another secondary objective is to assess the effectiveness of anticoagulant therapy in the patients who have suffered from a thrombotic event. In addition, we aim to study the changes in coagulation parameters in a cancer patient at baseline and after a thrombotic event. | — |
Countries
The Netherlands
Outcome results
None listed